Bringing together vaccinia’s natural attributes with novel genetic engineering, Genelux has designed its proprietary vaccinia virus-based vectors to deliver a four- pronged attack against cancer:

Genelux has pioneered a new therapeutic and diagnostic product platform utilizing an attenuated (Lister strain) oncolytic vaccinia virus to specifically enter and destroy solid tumors and distant metastases without harming healthy tissues and organs. Vaccinia virus is one of the most promising oncolytic viruses currently being tested in human clinical trials and has selected it as a backbone for its novel cancer therapies and diagnostics. Our platform technology can work alone (as a monotherapy), synergistically with existing marketed therapies as a combination therapy (including chemo, radiation therapy, monoclonal antibodies, etc.).

1. Highly specific replication in and lysis of tumor cells

Our vaccinia-based oncolytic viral platform takes advantage of the natural selectivity of the virus to enter and replicate within tumors and metastases. The virus infects and replicates within tumor cells. Tumor cells are killed (lysed) as the amplifying viral load causes the cells to burst and viral progeny to infect neighboring tumor cells.

2. Destruction of Tumor Vasculature

The network of blood vessels surrounding a tumor that once fueled the cancer’s growth is destroyed as the oncolytic process results in production of chemokines and cytokines, which attract neutrophils to the tumor, causing intravascular thrombosis and avascular necrosis. Vaccinia strains are also capable of infecting tumor-associated endothelial cells whose destruction may also contribute to vascular collapse.

3. Activation of the innate and adaptive immune response against tumors

In addition to direct lysis (killing) of tumor cells, the Genelux vaccinia-based oncolytic viral platform also harnesses the body’s innate and adaptive immune response in the fight against cancer; in fact, our research shows that the immune system ultimately induces clearance of virally-infected tumors, much in the way immune-mediated tissue rejection occurs. Moreover, preclinical evidence suggests that this process can train the body’s immune system to inhibit the formation of future tumors.

4. Armed with engineered genetic payloads (EGPs) for specific delivery and amplification in tumor cells to achieve potent anti-cancer therapy and diagnosis

Genelux specializes in the development of customized viral vectors that carry desired transgenes (engineered genetic payloads) to be manufactured or over-expressed directly within the tumor for a number of specific purposes. Leveraging the unique mechanisms by which its proprietary vaccinia platform preferentially targets and kills tumor cells, the company has designed and constructed over 500 unique transgenes or proteins and can efficiently design and construct custom viral vectors for future drug candidates.